J Am Pharm Assoc (2003). 2022 Nov-Dec;62(6):1741-1749.e10. doi: 10.1016/j.japh.2022.06.014. Epub 2022 Jul 3.
Osteoporosis is a major public health concern, given that disease prevalence is expected to substantially increase due to the aging population. Community pharmacists can play a key role in the identification and management of chronic diseases.
The purpose of this systematic review was to present an overview of the literature on the role of community pharmacists in providing osteoporosis interventions to patients. The secondary objective was to assess the impact of these interventions on patient outcomes.
A literature search was conducted in Embase, CINAHL, Scopus, MEDLINE, and Web of Science from database inception to March 2021. The search was limited to human studies in the English language. Primary studies were included if they described or assessed a patient-directed osteoporosis intervention conducted by community pharmacists. The following data were extracted and tabulated: citation, study location, study design, subject, number of participants, nature of intervention, classification of intervention, outcome measures, measurement methods, findings, and effect. Risk of bias was assessed using the Cochrane Risk of Bias tool for randomized trials (RoB 2) and Risk of Bias in Non-randomized Studies (ROBINS-I).
Twenty-one studies were included in this review. The main interventions were education, screening, and medication management. Nineteen of these studies reported patient outcomes, all yielding positive outcomes. Outcomes included increased physician follow-up, risk factor reduction, increased osteoporosis knowledge, increased medication adherence, identification of medication-related problems, and positive patient-reported experience measures (PREMs). Three studies were considered to have a moderate risk of bias, whereas the remaining 18 studies had a high risk of bias.
There is some evidence that pharmacist-led osteoporosis interventions have a positive impact on patient outcomes. More high-quality studies using objective outcome measures are needed to determine whether this translates into clinical outcomes such as decreased hospitalization and fractures.
由于人口老龄化,预计疾病患病率将大幅增加,骨质疏松症成为一个主要的公共卫生关注点。社区药剂师可以在慢性病的识别和管理中发挥关键作用。
本系统评价旨在综述社区药剂师在为患者提供骨质疏松症干预措施方面的作用的文献。次要目的是评估这些干预措施对患者结局的影响。
从数据库建立到 2021 年 3 月,在 Embase、CINAHL、Scopus、MEDLINE 和 Web of Science 中进行了文献检索。检索仅限于英文人类研究。如果描述或评估了由社区药剂师实施的针对患者的骨质疏松症干预措施,则纳入了原始研究。提取并列表记录了以下数据:引文、研究地点、研究设计、研究对象、参与者人数、干预性质、干预分类、结局指标、测量方法、发现和效果。使用针对随机试验的 Cochrane 偏倚风险工具(RoB 2)和针对非随机研究的偏倚风险(ROBINS-I)评估偏倚风险。
本综述纳入了 21 项研究。主要干预措施为教育、筛查和药物管理。其中 19 项研究报告了患者结局,所有研究均得出积极的结果。结局包括增加医生随访、降低风险因素、增加骨质疏松症知识、提高药物依从性、发现药物相关问题以及正面的患者报告体验测量(PREMs)。有 3 项研究被认为存在中度偏倚,而其余 18 项研究存在高度偏倚。
有一些证据表明,药剂师主导的骨质疏松症干预措施对患者结局有积极影响。需要更多使用客观结局测量的高质量研究,以确定这是否转化为临床结局,如减少住院和骨折。